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ABSTRACT
Introduction: Asthma is an inflammatory condition of the lungs that can have
significant impacts on a patient’s quality of life. Asthma attacks can be very
uncomfortable and even deadly in some cases. The objective of this study is to evaluate
the treatment of asthma in the state of Mississippi and to describe the disparities between
demographics to help healthcare providers identify patients who might be at risk for poor
treatment and help those patients receive quality healthcare. Methods: The data was
retrospectively collected from January to December 2014 Mississippi Centers for
Medicare and Medicaid Services claims data. This study is a retrospective, longitudinal,
analytical, non-experimental design to describe the quality of asthma treatment in the
state of Mississippi. The study uses two measures from the Healthcare Effectiveness Data
and Information Set (HEDIS), the Asthma Medication Ratio (AMR) and Medication
Management for People With Asthma (MMA). Results: The results are split into two
main categories, AMR and MMA. The AMR section is then divided into categories for
age, race, and sex. The MMA measure is further divided into Proportion of Days
Covered>50% (PDC50) and Proportion of Days Covered>75% (PDC75) for the
categories of age, race, and sex. The results showed significant differences among
demographics for each measure except for MMA PDC75 by Sex. Discussion: These
differences could be due to medication adherence issues, the misclassification of
intermittent asthma as persistent asthma, or limitations within the measures.
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BACKGROUND

Description of the Problem
According to the Center for Disease Control and Prevention, as of 2017,
there were over 25 million Americans living with asthma, or, roughly, 8% of the
population. There were also over 3,500 deaths, in 2017, with asthma as the main cause.
The CDC also states that there are 187,772 people in Mississippi living with asthma, or
8.3% of the state population. Mississippi had 47 deaths attributable to asthma in 2017
(Asthma State Data, 2019). Though the state average is close to the national average for
citizens living with asthma, the mean of Mississippians, especially children, living with
uncontrolled asthma is significantly higher than the national average, with 53.1% of
children in Mississippi vs 38.4% of children nationally (AsthmaStats 2014). According to
the Asthma and Allergy Foundation of America, between 2008 and 2013, asthma
accounted for over $50 billion in medical costs alone, not including the other economic
costs associated with it. This averages over $6 billion per year. (AAFA)

Causes of Asthma
Asthma is a chronic lung disease that causes the airways to be inflamed and
narrow, making it difficult to breathe. During an exacerbation, symptoms worsen, making
it even harder to breathe. Symptoms of an asthma exacerbation include; wheezing,
shortness of breath, tachypnea (rapid breathing), and coughing. If severe enough, the
asthma exacerbation can be life threatening with symptoms such as cyanosis (a condition
where the lips and fingertips turn blue from lack of oxygen), flaring of the nostrils, very
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fast movement of the stomach or ribs with breathing, incomplete exhalation, or, in
infants, unresponsiveness to parents. (AAFA)
Asthma exacerbations can be triggered by a several different factors, including
physical activity, allergens, or occupational factors such as fumes or dust. When an
irritant encounters a patient with asthma’s airways, the airways become inflamed and
constricted, causing the symptoms seen in asthma exacerbations. (AAAI)

Treatment of Asthma
The two main types of medication used to treat asthma are controller and reliever
medications. Controller medications are taken prophylactically every day to prevent
asthma exacerbations and control the daily symptoms of asthma. Types of controller
medications include: inhaled corticosteroids, inhaled corticosteroid combinations, long
acting beta-2 agonists, leukotriene modifiers, mast cell stabilizers, methylxanthines, and
immune modulators. Reliever medications are typically short-acting, inhaled beta-2
agonists. The treatment of asthma is dependent on whether it is classified as intermittent
or persistent. The differences in these two classes can be seen in Appendix B. Intermittent
asthma does not require a controller medication while persistent does and could require
multiple (Asthma Quick Care Reference, 2012).

Quality Control Measures
Quality of care, as defined by the Institute of Medicine, is “the degree to which
health services for individuals and populations increase the likelihood of desired health
outcomes and are consistent with current professional knowledge” (Lohr, 1990). As
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different options for health insurance began to arise in the 20th century, so too did the
need for a way to measure the quality of care received by patients. The need partly arose
from economic reasons and partly from a wellbeing of the patient side. The patients
needed to know that they were going to receive the best healthcare possible and the
insurance company wanted to ensure that their money was being spent efficiently on
capable doctors and hospitals (McIntyre et al, 2001). The National Committee on Quality
Assurance (NCQA) created the Healthcare Effectiveness and Data Information Set
(HEDIS) as a quality control measure to be used by consumers and insurers alike. HEDIS
is composed of six domains of care composed of ninety quality control measures.
According to the NCQA website, “191 million people are enrolled in plans that report
HEDIS results,” which is over half the United States population according to recent
census data (HEDIS) (US Census Bureau, 2011).
This study will be using the HEDIS Asthma Medication Ratio (AMR) and
Medication Management for People with Asthma (MMA) quality control measures.
AMR is the ratio of controller medications to total asthma medications. MMA measures
the mean of people who remain on a controller medication for at least 50% of their
treatment period and the mean of people who remain on a controller medication for at
least 75% of their treatment period.

Medicare and Medicaid
In 1965, Congress added amendments XVIII and XIX to the Social Security Act,
establishing Medicare and Medicaid, respectively. Medicare gives coverage to all citizens
over the age of 65, regardless of past medical history. Medicaid is meant to give coverage
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to lower income citizens; however, it is made to be state run but was not made mandatory
for each state to have a program. Both programs are administered by the Centers for
Medicare and Medicaid Services (CMS).
There have been several changes to Medicare since 1965. Currently it is divided
into 4 parts: Part A, Part B, Part C, and Part D. Medicare provides coverage to anybody
over the age of 65, people with end stage renal-disease or amyotrophic lateral sclerosis,
and some disabled people under the age of 65. As well as the previously mentioned
health status’, in order to be eligible for Medicare a person must also be a citizen and
he/she or their spouse must have worked in a Medicare eligible job for at least ten years.
Part A, also known as Hospital Insurance (HI), is paid for through the HI Trust Fund
which is funded through payroll tax and also partly through a deductible paid by the
patient. It covers in-patient hospital visits, care at a skilled nursing facility, home health,
and hospice care. There is also automatic enrollment for Part A. Part B, also known as
Supplementary Medical Insurance (SMI), is paid for through the SMI Trust Fund, which
is funded through patient premiums and through revenues from the federal government.
Part B covers most outpatient visits and some drugs, such as those that cannot be
administered by the patient, but it does not cover hearing, vision, dental, or most
prescription drugs. To be eligible for Part B, the patient must also be enrolled in Part A
however, enrollment in Part B is voluntary and not automatic. Part C, also known as
Managed Care, is a plan available to those enrolled in Part A and Part B. Part C is a
program where the patient is enrolled in a private insurance company but Medicare is
paying a predetermined amount to the company to offset the cost. These plans are
required to cover the same elements as Part A and Part B but can cover more. Many Part
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C plans also offer coverage for prescription drugs, vision, dental, and hearing.
Beneficiaries of these plans pay the Part B premium as well as an additional premium for
any additional coverage. Medicare Part D is available to those enrolled in Part A and Part
B. Part D is funded through the SMI Trust Fund and covers prescription drugs.
Beneficiaries are allowed to choose their own prescription drug plan. These plans must
include a Medication Therapy Management program to help increase patient
understanding, adherence, and decrease adverse events.
Whereas Medicare is almost exclusively for people over the age of 65, with some
exceptions, Medicaid is for people of any age who do not have the means to afford
healthcare on their own. It is funded by both the state and federal governments, with the
federal government contributing an amount proportional to the state’s average income
level. Medicaid is also administered by the individual state, with some national
guidelines. There are three groups covered under Medicaid: the Mandated Categorically
Needy, Optionally Categorically Needy, and Medically Needy. The Mandated
Categorically Needy includes children under the age of 19 whose family’s income is less
than 138% of the Federal Poverty Line (FPL), pregnant women whose income is less
than 133% of the FPL, parents who receive welfare, and people with disabilities who
receive a Supplemental Security Income below 79% of the FPL. The Optionally
Categorically Needy category is determined by the states but must include the same
benefits and coverage as the Mandated category. The Medically Needy category includes
individuals who make above the FPL thresholds to fit into another category but spend so
much on medical expenses that their income falls below a state established line
(Ramachandran, 2018).
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Study Significance
This study will help to identify specific at-risk populations for poor treatment of
asthma in the state of Mississippi. This will help healthcare providers, such as primary
care providers, pharmacists, and nurses, to be more vigilant in identifying and assisting in
suboptimal treatment. In preparation for this study, a literature review was conducted,
and it was found that a similar study was conducted in one aspect by the Mississippi Drug
Utilization Review Board (Asthma Overview, 2019); however, that study was much
smaller in comparison to the one conducted for this paper.

Study Objectives
The objectives of this study are:
1. To evaluate the performance on HEDIS Medication Management for people with
Asthma (MMA) and Asthma Medication Ratio (AMR) among patients with
persistent asthma using claims data from CMS Medicaid.
2. To describe the demographic variations of MMA and AMR for patients enrolled
in Mississippi Medicaid with persistent asthma.
3. To explore ways to improve MMA and AMR disparities throughout the state of
Mississippi.
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Methods
Design
The study was conducted using a retrospective, longitudinal, analytical, nonexperimental design to describe the quality of asthma treatment in the state of Mississippi
using Mississippi Centers for Medicare and Medicaid Services claims data. This study is
approved by the University of Mississippi Institutional Review Board, the protocol
number is 19-051.

Sample
The sampled data is consistent with the parameters set forth by HEDIS
AMR and MMA measures. See Appendix A for AMR and MMA measures, respectively.
The study was conducted using Mississippi Centers for Medicare and Medicaid Services
claims data for calendar year 2014. Beneficiaries with persistent asthma were identified
and classified as receiving appropriate treatment or not using the specifications in the
HEDIS quality measures for asthma treatment. Demographic characteristics of
beneficiaries were determined from the CMS beneficiary summary files and
comorbidities were identified using medical claims for the beneficiaries included in the
study. The AMR set consists of 17,997 patients and the MMA set consists of 14,014
patients. The difference is that the AMR measure excludes patients who received no
asthma medications, whether controller or reliever, while the MMA measure only
excludes patients who did not receive any controller medications.

7

Data Collection and Analysis
All data collected was retrospective claims data from the Mississippi Centers for
Medicare and Medicaid Services. Descriptive statistics and logistic regressions will be
used to compare performance on the HEDIS measures across beneficiary characteristics
and to identify disparities in the treatment of asthma in Mississippi.
The AMR is the ratio of controller asthma medications to total asthma
medications. The ideal ratio is greater than 0.5, where no other medications are needed,
and the asthma is controlled.
The MMA measure is quantified by using the Proportion of Days Covered (PDC).
This is the proportion of days on an asthma controller medication related to the total
number of days in the treatment period. The first category is PDC50, which is the number
of persons who were on a controller medication for over 50% of the treatment period.
The second category is PDC75, which is the number of persons who were on a controller
medication for over 75% of the treatment period. For this study, the study population was
assigned numerical values to measure the PDC50 and PDC75. Those with a score of
PDC<50% or PDC<75% are deemed unfavorable outcomes. Those with a score of
PDC>50% or PDC>75% are deemed favorable outcomes.

8

Results
The AMR measure was composed of 17,997 individuals ranging from 5 years old
to 64 years old representing six racial categories. Table 1 shows the frequency and mean
of the overall population with an AMR of less than or greater than or equal to 0.5.
Approximately 69.01% of the population received an AMR greater than or equal to 0.5.
As shown in Table 2, the average age was 16 years old with 12 years old being the
median. Tables 3 shows the frequency and mean for each age group.
Table 4 shows the analysis of AMR by a function of the age group demographic,
with the associated Chi-Square Test. Approximately 79.23% of 5-11 year olds, 68.06% of
12-18 year olds, 43.51% of 19-50 year olds, and 58.48% of 51-64 year olds, had an AMR
score of 0.5 or greater. The Chi-Square Test gives a p-value of less than 0.0001. This
means that for the 95% confidence interval, there is a statistically significant difference
between the groups.
Table 5 shows the frequency and mean for each racial demographic. Table 6
shows the analysis of AMR by a function of the race demographic with the associated
Chi-Square Test. Approximately 66.19% of African Americans, 74.07% of American
Indians, 88.52% of Asians, 74.49% of Caucasians, 69.52% of Hispanics, and 66.95% of
the Unknown/Other category, had an AMR score of 0.5 or greater. The Chi-Square Test
gives a p-value of less than 0.0001. This means that for the 95% confidence interval,
there is a statistically significant difference between the groups.
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Table 7 shows the frequency and mean for males and females. Table 8 shows the
analysis of AMR by a function of sex, with the corresponding Chi-Square Test.
Approximately 64.89% of females had an AMR score of 0.5 or greater while 72.98% of
males did. The Chi-Square Test gives a p-value of less than 0.0001. This means that for
the 95% confidence interval, there is a statistically significant difference between the
groups.
The MMA measure was composed of 14,014 individuals broken down into the
same demographic categories as the AMR measure. The data is divided into two sections,
PDC50 and PDC75, and further divided into race, sex, and age group. The overall PDC50
and PDC75 data is shown in Tables 9 and 10, respectively. For PDC50, approximately
41.07% of individuals received a score of 1. For PDC75, approximately 18.10% of
individuals received a score of 1.
Table 11 shows the frequency and mean of the age group categories for the
MMA measure. Table 12 shows the analysis of PDC50 by age group, with the
associated Chi-Square Test. Approximately 41.27% of 5-11 year olds, 37.97% of 12-18
year olds, 43.91% of 19-50 year olds, and 53.89% of 51-64 year olds, received a score
of 1. The Chi-Square Test gives a p-value of less than 0.0001. This means that for the
95% confidence interval, there is a statistically significant difference between the
groups.
In Table 13 the analysis of PDC75 is shown by age group, with the associated
Chi-Square Test. Approximately 17.64% of 5-11 year olds, 15.91% of 12-18 year olds,
21.79% of 19-50 year olds, and 31.11% of 51-64 year olds, received a score of 1. The
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Chi-Square Test gives a p-value of less than 0.0001. This means that for the 95%
confidence interval, there is a statistically significant difference between the groups.
Table 14 shows the frequency and mean of the racial group categories for the
MMA measure. In Table 15, the analysis of PDC50 is shown by race, with the
corresponding Chi-Square Test. Approximately 36.39% of African Americans, 37.50%
of American Indians, 43.40% of Asians, 50.96% of Caucasians, 42.08% of Hispanics,
and 50.32% of Unknown/Others, received a score of 1. The Chi-Square Test gives a pvalue of less than 0.0001. This means that for the 95% confidence interval, there is a
statistically significant difference between the groups.
Table 16 shows the analysis of PDC75 by race, with the corresponding ChiSquare Test. Approximately 14.17% of African Americans, 12.50% of American Indians,
28.30% of Asians, 25.89% of Caucasians, 18.33% of Hispanics, and 28.46% of
Unknown/Others, received a score of 1. The Chi-Square Test gives a p-value of less than
0.0001. This means that for the 95% confidence interval, there is a statistically significant
difference between the groups.
Table 17 shows the frequency and mean of the males and females for the MMA
measure In Table 18, the analysis of PDC50 is shown by sex, with the corresponding
Chi-Square Test. Approximately 40.11% of females and 41.90% of males received a
score of 1. The Chi-Square Test gives a p-value of 0.0312. This means that for the 95%
confidence interval, there is a statistically significant difference between the groups.
Table 19 shows the analysis of PDC75 by sex, with the corresponding Chi-Square
Test. Approximately 17.82% of females and 18.33% of males received a score of 1. The
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Chi-Square Test gives a p-value of 0.4377. This means that for the 95% confidence
interval, there is no significant difference with regard to individual’s sex.
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AMR Tables:
Table 1: Overall AMR

AMR

Frequency (n)

Mean (%)

< 0.5

5578

30.99

> 0.5

12419

69.01

Table 2: AMR and Age Statistics

Variable

Mean

Median

Minimum

Maximum

AMR

0.69

1.00

0

1.00

Standard
Deviation
0.46

Age (years)

16.43

12.00

5.00

64.00

13.67

Table 3: Age Frequency for AMR Ratio

Age Group
(years)
05-11

Frequency (n)

Mean (%)

8,976

49.87

12-18

5,429

30.17

19-50

2,606

14.48

51-64

986

5.48
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Table 4: AMR by Age Groups

Age Group
(years)
Frequency
Row Mean
05-11

AMR
< 0.5

> 0.5

Total

1864 (20.77)

7112 (79.23)

8,976

12-18

1734 (31.94)

3695 (68.06)

5,429

19-50

1472 (56.49)

1134 (43.51)

2,606

51-64

508 (51.52)

478 (48.48)

986

Totals

5,578 (30.99)

12,419 (69.01)

17,997

Table 5: Race Frequency for AMR Ratio

Race

Frequency (n)

Percent (%)

African
American
American
Indian
Asian

11,080

61.57

27

0.15

61

0.34

Caucasian

5728

31.83

Hispanic

269

1.49

Unknown/Other

832

4.62

14

p-value

< 0.0001

Table 6: AMR Ratio by Race

Race
Frequency
Row Mean
African
American
American Indian

< 0.5

AMR Ratio
> 0.5

Total

3,746 (33.81)

7,334 (66.19)

11,080

7 (25.93)

20 (74.07)

27

Asian

7 (11.48)

54 (88.52)

61

Caucasian

1461 (25.51)

4267 (74.49)

5,728

Hispanic

82 (30.48)

187 (69.52)

269

Unknown/Other

275 (33.05)

557 (66.95)

832

Totals

5,578 (30.99)

12,419 (69.01)

17,997

p-value

< 0.0001

Table 7: Sex Frequency for AMR Ratio

Sex
F

Frequency (n)
8,837

Mean (%)
49.10

M

9,160

50.90

Table 8: AMR by Sex

Sex
Frequency
Row Mean
Female

AMR
< 0.5

> 0.5

Totals

3103 (35.11)

5734 (64.89)

8,837

Male

2475 (27.02)

6685 (72.98)

9,160

Totals

5,578 (30.99)

12,419 (69.01)

17,997

15

p-value

< 0.0001

MMA Tables:

Table 9: Overall PDC50

PDC50

Frequency

Percent

0

8258

58.93

1

5756

41.07

Table 10: Overall PDC75

PDC75

Frequency (n)

Mean (%)

0

11478

81.90

1

2536

18.10

Table 11: MMA Measure Age Group Characteristics

Age Group
(years)
5-11

Frequency (n)

Mean (%)

7902

56.39

12-18

4085

29.15

19-50

1487

10.61

51-64

540

3.85
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Table 12: Age Group by PDC50

Age Group
(years)
Frequency
Row Mean
05-11

PDC50
PDC<50%
n (%)
4641 (58.73)

PDC>50%
n (%)
3261 (41.27)

Total

12-18

2534 (62.03)

1551 (37.97)

4085

19-50

834 (56.09)

653 (43.91)

1487

51-64

249 (46.11)

291 (53.89)

540

Total

8258 (58.93)

5756 (41.07)

14014

p-value

7902

< 0.0001

Table 13: Age Group by PDC75

Age Group
(years)
Frequency
Row Mean
05-11

PDC75
PDC<75%
n (%)
6508 (82.36)

PDC>75%
n (%)
1394 (17.64)

Total

12-18

3435 (84.09)

650 (15.91)

4085

19-50

1163 (78.21)

324 (21.79)

1487

51-64

372 (68.89)

168 (31.11)

540

Total

11478 (81.90)

2536 (18.10)

14014

17

p-value

7902

< 0.0001

Table 14: MMA Measure Demographic Characteristics

Race

Frequency (n)

Mean (%)

African
American
American Indian

9286

66.26

24

0.17

Asian

53

0.38

Caucasian

3789

27.04

Hispanic

240

1.71

Unknown/Other

622

4.44

Table 15: Race by PDC50

Race

PDC50

Frequency
Row Mean
African American

PDC<50%
n (%)
5907 (63.61)

PDC>50%
n (%)
3379 (36.39)

Total

American Indian

15 (62.50)

9 (37.50)

24

Asian

30 (56.60)

23 (43.40)

53

Caucasian

1858 (49.04)

1931 (50.96)

3789

Hispanic

139 (57.92)

101 (42.08)

240

Unknown/Other

309 (49.68)

313 (50.32)

622

Total

8258 (58.93)

5756 (41.07)

14014

18

p-value

9286

< 0.0001

Table 16: Race by PDC75

Race

PDC75

Frequency
Row Mean
African American

PDC<75%
n (%)
7970 (85.83)

PDC>75%
n (%)
1316 (14.17)

Total

American Indian

21 (87.50)

3 (12.50)

24

Asian

38 (71.70)

15 (28.30)

53

Caucasian

2808 (74.11)

981 (25.89)

3789

Hispanic

196 (81.67)

44 (18.33)

240

Unknown/Other

445 (71.54)

177 (28.46)

622

Total

11478 (81.90)

2536 (18.10)

14014

p-value

9286

< 0.0001

Table 17: MMA Measure Sex Characteristics

Sex

Frequency (n)

Mean (%)

F

6480

46.24

M

7534

53.76

Table 18: Sex by PDC50

Sex

PDC50

Frequency
Row Mean
Female

PDC<50%
n (%)
3881
59.89
4377
58.10
8258
58.93

Male
Total

PDC>50%
n (%)
2599
40.11
3157
41.90
5756
41.07

19

Total

p-value

6480
7534
14014

0.0312

Table 19: Sex by PDC75

Sex

PDC75

Frequency
Row Mean
Female

PDC<75%
n (%)
5325 (82.18)

PDC>75%
n (%)
1155 (17.82)

Total

Male

6153 (81.67)

1381 (18.33)

7534

Total

11478 (81.90)

2536 (18.10)

14014

20

p-value

6480
0.4377

Discussion

Asthma Medication Ratio Key Findings
Comparing AMR by age groups, the 05-11 year age group considerably
outperformed all the other groups. This could be due to adherence issues. If a patient has
trouble adhering to prescription instructions for a controller medication, which are
sometimes administered multiple times per day, the patient will need more non-controller
medications, such as rescue inhalers. This will shift the patient from what could be an
optimal treatment to a treatment with an unfavorable AMR. That age group is still
dependent on parents or guardians for their adherence and the parents may follow
instructions more closely to keep their children healthy. As the patient ages, he/she
become more independent and though he/she may be able to take his/her medications
independently, he/she may not to remember to take his/her controller medication. This
explanation also provides a reason why the 51-64 year age group, outperformed the 19-50
age group, as an older patient may be more responsible and more likely to take care of
their health and have better medication adherence (Hadji et al, 2016)
In AMR by Race, the African American group performed the worst, despite
having the same insurance and, theoretically, access to the same healthcare providers.
Similar to how adherence is the reason the 05-11 year age group performed the best,
adherence could be the reason African Americans performed the worst. These issues
could be due to cultural barriers, poor health literacy, or poor patient education.
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For males and females, males performed significantly better than females. This
could also be due to females being more likely to visit their physician and have their
medications changed, which would alter the AMR.

Medication Management for People With Asthma Key Findings
MMA measures medication adherence by using claims data from pharmacies.
Looking at the 12-18 year age group by PDC50 and Age Group by PDC75, they
performed the worst according to the MMA measures with the 05-11 year ago group
performing the second worst. This could be due to the misclassification of mild asthma as
persistent asthma skewing the results. After the 12-18 year age group, the PDC50 and
PDC75 increases as age increases, showing increased adherence. This could be due to
fewer misclassifications or patients are starting to take their healthcare more seriously
and getting better about taking their medication. The average value for PDC50 was
41.07%, when this is changed to PDC75, the value drops to 18.10%, a relative change of
-55.97%. This change is similar to what the majority of the demographics experienced.
This data is also could also be skewed by patients not correctly diagnosed with persistent
asthma. It also is very telling as to how poorly these controller medications are actually
taken. Throughout both AMR and MMA measures, every group was statistically
significantly different with the exception of one, Sex by PDC75. It had a p-value of
0.4377 meaning that there is not a statistically significant difference in sex. This is most
likely due to males and females sharing more of the same influences on adherence than
people of different age groups or racial groups.
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Study Limitations
The main limitation of this study is that it may not be generalizable to other
populations because the data was derived from Medicaid claims data. People who are
enrolled in Medicaid are generally associated with a lower socioeconomic status. People
of a higher socioeconomic status might have access to more doctors and medications not
available to Medicaid patients due to factors associated with a lower socioeconomic
status, such as limitations in number of specialized providers in an area or barriers in
transportation to providers. A lower socioeconomic status is also generally associated
with poor health literacy which could affect medication adherence (Wamala et al, 2007).
People with Medicaid insurance are also limited to 6 prescriptions per month and might
be less likely to fill a controller prescription as they would a reliever prescription.
Another limitation is the study uses claims data from the year 2014, which is just one
year of data. Both measures also include patients who have had four medication
dispensing events. This allows for the opportunity of misclassification of patients with
intermittent asthma as patients with persistent asthma. The measures are for patients with
persistent asthma, but medication dispensing events is not in the criteria for the
classification of asthma so there is not a guarantee the patients have persistent asthma.
For AMR, one way the data can become skewed is if a patient goes through many
different controller medications throughout the year. This would skew the data because
the ratio would be falsely high due to the amount of controller medications, offsetting the
non-controller medications. There are multiple ways the MMA data can be skewed. If a
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person is not correctly diagnosed with persistent asthma, fits the inclusion criteria, is
started on controller medication, but later reclassified as intermittent asthma, or even no
asthma at all, and treatment of controller medications is discontinued, those patients will
still be included in the measure. The MMA data could also be skewed by patients using
asthma controller medications for seasonal asthma, where they are only adherent to their
medications for a certain portion of the year. Many people also visit urgent care clinics
instead of their primary care physician for medical care, this could be a source of error as
many urgent care offices might not have access to spirometry, a tool needed to accurately
diagnose and assess asthma. There is also no guarantee the patient took the medication,
only that the prescription was filled. These two sources of error could account for the
reason why the PDC50 and PDC75 mean value for 1 was low.

Practical Relevance
With certain groups being identified as falling behind other groups in terms of
performance, healthcare professionals can use this data to try to mediate the disparity.
Pharmacists, in particular, can be sure to be more vigilant about educating patients about
the difference in controller and reliever medications and the importance of proper
technique and adherence. This would improve health outcomes and performance on
quality control measures. Pharmacists can also be more vigilant about ensuring that
patients with persistent asthma have a controller medication as a part of their medication
regimen.
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Ideas for Future Research
For future research, it would be advantageous to change the exclusion criteria to
exclude people whose asthma diagnoses have been downgraded from persistent to
intermittent. It would also be beneficial to do a similar study showing the variation by
geographic region. This could help to identify areas of the state that are consistently
underperforming so that these problems can be addressed.
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Appendix A
Asthma Medication Ratio (AMR)
SUMMARY OF CHANGES TO HEDIS 2017
• No changes to this measure.

Description
The mean of members 5–85 years of age who were identified as having persistent asthma and
had a ratio of controller medications to total asthma medications of 0.50 or greater during the
measurement year.
Note: For Medicaid, report only members 5–64 years of age. For Medicare, report only members
18–85 years of age.

Definitions
Oral medication
dispensing
event

One prescription of an amount lasting 30 days or less. To calculate dispensing events
for prescriptions longer than 30 days, divide the days supply by 30 and round down to
convert. For example, a 100-day prescription is equal to three dispensing events
(100/30 = 3.33, rounded down to 3). Allocate the dispensing events to the appropriate
year based on the date on which the prescription is filled.
Multiple prescriptions for different medications dispensed on the same day are counted
as separate dispensing events. If multiple prescriptions for the same medication are
dispensed on the same day, sum the days supply and divide by 30. Use the Drug ID to
determine if the prescriptions are the same or different.
Refer to the definition of Oral medication dispensing event in MMA for examples.

Inhaler
dispensing
event

When identifying the eligible population, use the definition below to count
inhaler dispensing events.
All inhalers (i.e., canisters) of the same medication dispensed on the same day
count as one dispensing event. Medications with different Drug IDs dispensed
on the same day are counted as different dispensing events. For example, if a
member received three canisters of Medication A and two canisters of
Medication B on the same date, it would count as two dispensing events.
Allocate the dispensing events to the appropriate year based on the date
when the prescription was filled.
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Use the Drug ID field in the NDC list to determine if the medications are the same or
different.
Injection
dispensing
event

Each injection counts as one dispensing event. Multiple dispensed injections of the
same or different medications count as separate dispensing events. For example, if a
member received two injections of Medication A and one injection of Medication B on
the same date, it would count as three dispensing events.
Allocate the dispensing events to the appropriate year based on the date when the
prescription was filled.
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Units of
medications

When identifying medication units for the numerator, count each individual
medication, defined as an amount lasting 30 days or less, as one medication
unit. One medication unit equals one inhaler canister, one injection, or a 30day or less supply of an oral medication. For example, two inhaler canisters of
the same medication dispensed on the same day count as two medication
units and only one dispensing event.
Use the package size and units columns in the NDC list to determine the
number of canisters or injections. Divide the dispensed amount by the package
size to determine the number of canisters or injections dispensed. For
example, if the package size for an inhaled medication is 10 g and pharmacy
data indicates the dispensed amount is
30 g, this indicates 3 inhaler canisters were dispensed.

Eligible Population
Note: Members in hospice are excluded from the eligible population. Refer to General Guideline
20: Members in Hospice.
Product lines

Commercial, Medicaid, Medicare (report each product line separately).

Ages

For commercial, ages 5-85 as of December 31 of the measurement year. Report the
following age stratifications and total rate:
• 5–11 years.

• 51–64 years.

• 12–18 years.

• 65–85 years.

• 19–50 years.

• Total.

For Medicaid, ages 5–64 as of December 31 of the measurement year. Report the
following age stratifications and total rate:
• 5–11 years.

• 51–64 years.

• 12–18 years.

• Total.

• 19–50 years.
For Medicare, ages 18–85 as of December 31 of the measurement year. Report the
following age stratifications and total rate:
• 18-50 years.
• 51–64 years.

• 65–85 years.
• Total.

The total is the sum of the age stratifications for each product line.
Continuous
enrollment

The measurement year and the year prior to the measurement year.

Allowable gap

No more than one gap in enrollment of up to 45 days during each year of continuous
enrollment. To determine continuous enrollment for a Medicaid beneficiary for whom
enrollment is verified monthly, the member may not have more than a 1-month gap in
coverage during each year of continuous enrollment year.

Anchor date

December 31 of the measurement year.

Benefits

Medical. Pharmacy during the measurement year.
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Event/
diagnosis

Follow the steps below to identify the eligible population.
Step 1

Identify members as having persistent asthma who met at least one of the following
criteria during both the measurement year and the year prior to the measurement year.
Criteria need not be the same across both years.
• At least one ED visit (ED Value Set), with a principal diagnosis of asthma
(Asthma Value Set).
• At least one acute inpatient encounter (Acute Inpatient Value Set), with a
principal diagnosis of asthma (Asthma Value Set).
• At least four outpatient visits (Outpatient Value Set) or observation visits
(Observation Value Set), on different dates of service, with any diagnosis of
asthma (Asthma Value Set) and at least two asthma medication dispensing
events (Table MMA-A). Visit type need not be the same for the four visits.
• At least four asthma medication dispensing events (Table MMA-A).

Step 2

Step 3:
Required
exclusions

A member identified as having persistent asthma because of at least four asthma
medication dispensing events, where leukotriene modifiers or antibody inhibitors were
the sole asthma medication dispensed in that year, must also have at least one
diagnosis of asthma (Asthma Value Set), in any setting, in the same year as the
leukotriene modifier or antibody inhibitor (i.e., the measurement year or the year prior
to the measurement year).
Exclude members who met any of the following criteria:
• Members who had any diagnosis from any of the following value sets, any time
during the member’s history through December 31 of the measurement year:
– Emphysema Value Set.
– Other Emphysema Value Set.
– COPD Value Set.
– Obstructive Chronic Bronchitis Value Set.
– Chronic Respiratory Conditions Due to Fumes/Vapors Value Set.
– Cystic Fibrosis Value Set.
– Acute Respiratory Failure Value Set.
• Members who had no asthma medications (controller or reliever) dispensed
(Table AMR-A) during the measurement year.
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Administrative Specification
Denominator
Numerator

The eligible population.
The number of members who have a medication ratio of 0.50 or greater during the
measurement year. Follow the steps below to calculate the ratio.

Step 1

For each member, count the units of controller medications (Table AMR-A) dispensed
during the measurement year. Refer to the definition of Units of medications.

Step 2

For each member, count the units of reliever medications (Table AMR-A) dispensed
during the measurement year. Refer to the definition of Units of medications.

Step 3

For each member, sum the units calculated in step 1 and step 2 to determine units of
total asthma medications.

Step 4

For each member, calculate the ratio of controller medications to total asthma
medications using the following formula.
Units of Controller Medications (step 1)
Units of Total Asthma Medications (step
3)

Step 5

Sum the total number of members who have a ratio of 0.50 or greater in step 4.

Table AMR-A: Asthma Controller and Reliever Medications
Description
Antiasthmatic combinations
Antibody inhibitors
Inhaled steroid combinations
Inhaled corticosteroids

Leukotriene modifiers
Mast cell stabilizers
Methylxanthines
Description
Short-acting, inhaled beta-2
agonists

•
•
•
•
•
•

ASTHMA CONTROLLER MEDICATIONS
Prescriptions
Dyphylline-guaifenesin
• Guaifenesin-theophylline
Omalizumab
Budesonide-formoterol
• Fluticasone-salmeterol
Beclomethasone
• Flunisolide
Budesonide
• Fluticasone CFC free
Ciclesonide
• Mometasone

• Montelukast
• Zafirlukast
• Cromolyn
• Aminophylline
• Dyphylline
ASTHMA RELIEVER MEDICATIONS
Prescriptions
• Albuterol
• Levalbuterol

• Mometasone-formoterol

• Zileuton
• Theophylline

• Pirbuterol

Note: NCQA will post a comprehensive list of medications and NDC codes to www.ncqa.org by
November 1, 2016.
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Data Elements for Reporting
Organizations that submit HEDIS data to NCQA must provide the following data elements.

Table AMR-1/2/3: Data Elements for Asthma Medication Ratio
Data Elements
Measurement year
Data collection methodology (Administrative)
Eligible population
Number of required exclusions
Numerator events by administrative data
Numerator events by supplemental data
Reported rate
Lower 95% confidence interval
Upper 95% confidence interval

Administrative

For each age stratification and total
For each age stratification and total
For each age stratification and total
For each age stratification and total
For each age stratification and total
For each age stratification and total
For each age stratification and total

Medication Management for People With Asthma (MMA)
SUMMARY OF CHANGES TO HEDIS 2017
• No changes to this measure.

Description
The mean of members 5–85 years of age during the measurement year who were identified as
having persistent asthma and were dispensed appropriate medications that they remained on
during the treatment period. Two rates are reported:
1. The mean of members who remained on an asthma controller medication for at least 50%
of their treatment period.
2. The mean of members who remained on an asthma controller medication for at least 75%
of their treatment period.
Note: For Medicaid, report only members 5–64 years of age. For Medicare, report only members
18–85 years of age.

Definitions
IPSD

Index prescription start date. The earliest prescription dispensing date for any asthma
controller medication during the measurement year.

Treatment
period

The period of time beginning on the IPSD through the last day of the measurement year.

PDC

Proportion of days covered. The number of days that a member is covered by at least
one asthma controller medication, divided by the number of days in the treatment period.
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Oral
medication
dispensing
event

One prescription of an amount lasting 30 days or less. To calculate dispensing events
for prescriptions longer than 30 days, divide the days supply by 30 and round down to
convert. For example, a 100-day prescription is equal to three dispensing events
(100/30 = 3.33, rounded down to 3). Allocate the dispensing events to the appropriate
year based on the date when the prescription is filled.
Multiple prescriptions for different medications dispensed on the same day count as
separate dispensing events. If multiple prescriptions for the same medication are
dispensed on the same day, sum the days supply and divide by 30. Use the Drug ID to
determine if the prescriptions are the same or different.
• Two prescriptions for different medications dispensed on the same day, each with
a 60-day supply, equals four dispensing events (two prescriptions with two
dispensing events each).
• Two prescriptions for different medications dispensed on the same day, each with
a 15-day supply, equals two dispensing events (two prescriptions with one
dispensing event each).
• Two prescriptions for the same medication dispensed on the same day, each with
a 15-day supply, equals one dispensing event (sum the days supply for a total of
30 days).
• Two prescriptions for the same medication dispensed on the same day, each with
a 60-day supply, equals four dispensing events (sum the days supply for a total of
120 days).
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Inhaler
dispensing event

When identifying the eligible population, use the definition below to count inhaler
dispensing events.
All inhalers (i.e., canisters) of the same medication dispensed on the same day
count as one dispensing event. Medications with different Drug IDs dispensed on the
same day are counted as different dispensing events. For example, if a member
received three canisters of Medication A and two canisters of Medication B on the
same date, it would count as two dispensing events.
Allocate the dispensing events to the appropriate year based on the date when the
prescription was filled.
Use the Drug ID field in the NDC list to determine if the medications are the same or
different.

Injection
dispensing event

Each injection counts as one dispensing event. Multiple dispensed injections of the
same or different medications count as separate dispensing events. For example, if
a member received two injections of Medication A and one injection of Medication B
on the same date, it would count as three dispensing events.
Allocate the dispensing events to the appropriate year based on the date when the
prescription was filled.

Calculating
number of days
covered for the
numerator

If multiple prescriptions for different medications are dispensed on the same
day, calculate number of days covered by a controller medication using the
prescriptions with the longest days supply. For multiple different prescriptions
dispensed on different days with overlapping days supply, count each day within the
treatment period only once toward the numerator.
If multiple prescriptions for the same medication are dispensed on the same
or different day, sum the days supply and use the total to calculate the number
of days covered by a controller medication. For example, three controller
prescriptions for the same medication are dispensed on the same day, each with a
30-day supply, sum the days supply for a total of 90 days covered by a controller.
Subtract any days supply that extends beyond December 31 of the measurement
year.
Use the drug ID provided by the NDC to determine if the prescriptions are the same
or different.

Eligible Population
Note: Members in hospice are excluded from the eligible population. Refer to General Guideline
20: Members in Hospice.
Product lines

Commercial, Medicaid, Medicare (report each product line separately).

Ages

For commercial, ages 5-85 as of December 31 of the measurement year. Report the
following age stratifications and total rate:
• 5–11 years.

• 51–64 years.

• 12–18 years.

• 65–85 years.

• 19–50 years.

• Total.
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For Medicaid, ages 5–64 as of December 31 of the measurement year. Report the
following age stratifications and total rate:
• 5–11 years.

• 51–64 years.

• 12–18 years.

• Total.

• 19–50 years.
For Medicare, ages 18–85 as of December 31 of the measurement year. Report the
following age stratifications and total rate:
• 18-50 years.

• 65–85 years.

• 51–64 years.

• Total.

The total is the sum of the age stratifications for each product line.
Continuous
enrollment

The measurement year and the year prior to the measurement year.

Allowable gap

No more than one gap in enrollment of up to 45 days during each year of continuous
enrollment. To determine continuous enrollment for a Medicaid beneficiary for whom
enrollment is verified monthly, the member may not have more than a 1-month gap
in coverage during each year of continuous enrollment year.

Anchor date

December 31 of the measurement year.

Benefits

Medical. Pharmacy during the measurement year.

Event/diagnosis

Follow the steps below to identify the eligible population for the measure.

Step 1

Identify members as having persistent asthma who met at least one of the following
criteria during both the measurement year and the year prior to the measurement
year. Criteria need not be the same across both years.
• At least one ED visit (ED Value Set), with a principal diagnosis of asthma
(Asthma Value Set).
• At least one acute inpatient encounter (Acute Inpatient Value Set), with a
principal diagnosis of asthma (Asthma Value Set).
• At least four outpatient visits (Outpatient Value Set) or observation visits
(Observation Value Set) on different dates of service, with any diagnosis of
asthma (Asthma Value Set) and at least two asthma medication dispensing
events (Table MMA-A). Visit type need not be the same for the four visits.
• At least four asthma medication dispensing events (Table MMA-A).
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Table MMA-A: Asthma Medications
Description
Antiasthmatic combinations
Antibody inhibitor
Inhaled steroid combinations
Inhaled corticosteroids

•
•
•
•
•
•
•
•
•

Leukotriene modifiers
Mast cell stabilizers
Methylxanthines
Short-acting, inhaled beta-2
agonists

Prescriptions
• Guaifenesin-theophylline

Dyphylline-guaifenesin
Omalizumab
Budesonide-formoterol
Beclomethasone
Budesonide
Montelukast
Cromolyn
Aminophylline
Albuterol

•
•
•
•

Fluticasone-salmeterol
Ciclesonide
Flunisolide
Zafirlukast

• Dyphylline
• Levalbuterol

•
•
•
•

Mometasone-formoterol
Fluticasone CFC free
Mometasone
Zileuton

• Theophylline
• Pirbuterol

Note: NCQA will post a comprehensive list of medications and NDC codes to www.ncqa.org by
November 1, 2016.
Step 2

Step 3:
Required
exclusions

A member identified as having persistent asthma because of at least four asthma
medication dispensing events, where leukotriene modifiers or antibody inhibitors were the
sole asthma medication dispensed in that year, must also have at least one diagnosis of
asthma (Asthma Value Set), in any setting, in the same year as the leukotriene modifier or
antibody inhibitor (i.e., the measurement year or the year prior to the measurement year).
Exclude members who met any of the following criteria:
• Members who had any diagnosis from any of the following value sets, any time
during the member’s history through December 31 of the measurement year:
– Emphysema Value Set.
– Other Emphysema Value Set.
– COPD Value Set.
– Obstructive Chronic Bronchitis Value Set.
– Chronic Respiratory Conditions Due to Fumes/Vapors Value Set.
– Cystic Fibrosis Value Set.
– Acute Respiratory Failure Value Set.
• Members who had no asthma controller medications (Table MMA-B) dispensed
during the measurement year.

Table MMA-B: Asthma Controller Medications
Description
Antiasthmatic combinations
Antibody inhibitor
Inhaled steroid combinations
Inhaled corticosteroids
Leukotriene modifiers
Mast cell stabilizers
Methylxanthines

•
•
•
•
•
•
•
•

Dyphylline-guaifenesin
Omalizumab
Budesonide-formoterol
Beclomethasone
Budesonide
Montelukast
Cromolyn
Aminophylline

Prescriptions
• Guaifenesin-theophylline
•
•
•
•

Fluticasone-salmeterol
Ciclesonide
Flunisolide
Zafirlukast

• Dyphylline

•
•
•
•

Mometasone-formoterol
Fluticasone CFC free
Mometasone
Zileuton

• Theophylline

Note: NCQA will post a comprehensive list of medications and NDC codes to www.ncqa.org by
November 1, 2016.
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Administrative Specification
Denominator

The eligible population.

Numerators
Medication
Compliance 50%

The number of members who achieved a PDC of at least 50% for their asthma
controller medications (Table MMA-B) during the measurement year.

Medication
Compliance 75%

The number of members who achieved a PDC of at least 75% for their asthma
controller medications (Table MMA-B) during the measurement year. Follow the steps
below to identify numerator compliance.

Step 1

Identify the IPSD. The IPSD is the earliest dispensing event for any asthma controller
medication (Table MMA-B) during the measurement year.

Step 2

To determine the treatment period, calculate the number of days beginning on the IPSD
through the end of the measurement year.

Step 3

Count the days covered by at least one prescription for an asthma controller
medication (Table MMA-B) during the treatment period. To ensure that a days
supply that extends beyond the measurement year is not counted, subtract any
days supply that extends beyond December 31 of the measurement year.

Step 4

Calculate the member’s PDC using the following equation. Round (using the .5 rule) to
two decimal places.
Total Days Covered by a Controller Medication in the Treatment Period (step 3)
Total Days in Treatment Period (step 2)

Medication
Compliance 50%

Sum the number of members whose PDC is ≥50% for their treatment period.

Medication
Compliance 75%

Sum the number of members whose PDC is ≥75% for their treatment period.

Data Elements for Reporting
Organizations that submit HEDIS data to NCQA must provide the following data elements.

Table MMA-1/2/3: Data Elements for Medication Management for People With
Asthma
Data Elements
Measurement year

Administrative

Data collection methodology (Administrative)
Eligible population
Number of required exclusions
Numerator events by administrative data
Numerator events by supplemental data
Reported rate
Lower 95% confidence interval
Upper 95% confidence interval

Each rate, for each age stratification and total
Each rate, for each age stratification and total
Each rate, for each age stratification and total
Each rate, for each age stratification and total
Each rate, for each age stratification and total
Each rate, for each age stratification and total
Each rate, for each age stratification and total
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Appendix B

(Asthma Quick Care Reference, 2012)
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